Axicabtagene ciloleucel - Kite Pharma
Alternative Names: Anti-CD19-CAR-lentiviral-vector-transduced-autologous-T-cells-Kite-Pharma; Anti-CD19-CAR-PBL-Kite-Pharma/NCI; Anti-CD19-CAR-T-cell-therapy-Kite-Pharma/NCI; Anti-CD19-CAR-transduced-T-cells-Kite-Pharma/NCI; Anti-CD19-chimeric-antigen-receptor-lentiviral-vector-transduced-autologous-T-cells-Kite-Pharma; Anti-CD19-chimeric-antigen-receptor-peripheral-blood-lymphocytes-Kite-Pharma; Anti-CD19-chimeric-antigen-receptor-T-cells-Kite-Pharma/NCI; Anti-CD19-chimeric-antigen-receptor-transduced-T-cells-Kite-Pharma/NCI; anti-human CD19 CAR-T cell injection; Axi-cel®; Ejilunsai injection; FKC 876; KTE-C19; KTE-C19 CAR; YESCARTA; Yescarta; Yi Kai Da; YIKAIDALatest Information Update: 13 Sep 2024
At a glance
- Originator Cabaret Biotech
- Developer Daiichi Sankyo Inc; Genentech; Gilead Sciences K.K.; H. Lee Moffitt Cancer Center and Research Institute; Kite Pharma; Kite Pharma - Fosun Pharma (JV)
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Preregistration Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Phase II Haematological malignancies; Solid tumours
- No development reported Leukaemia
Most Recent Events
- 13 Jun 2024 Efficacy and adverse event data from the phase II ZUMA-24 trial presented at the 29th Congress of the European Haematology Association (EHA-2024)
- 11 Dec 2023 Efficacy and adverse event data from the phase II ZUMA-5 trial in Non-Hodgkin's lymphoma released byGilead Sciences
- 11 Dec 2023 Efficacy and safety data from a phase II trial in B cell lymphoma released by Kite Pharma